Acadia Pharmaceuticals Inc (NASDAQ: ACAD) kicked off on Monday, down -1.28% from the previous trading day, before settling in for the closing price of $14.81. Over the past 52 weeks, ACAD has traded in a range of $14.15-$32.59.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 27.73% over the past five years. While this was happening, its average annual earnings per share was recorded 246.15%. With a float of $164.61 million, this company’s outstanding shares have now reached $164.65 million.
Let’s look at the performance matrix of the company that is accounted for 598 employees. In terms of profitability, gross margin is 91.72%, operating margin of 2.56%, and the pretax margin is 5.14%.
Acadia Pharmaceuticals Inc (ACAD) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Acadia Pharmaceuticals Inc is 0.76%, while institutional ownership is 97.59%. The most recent insider transaction that took place on Aug 19 ’24, was worth 148,720. In this transaction EVP, CHIEF FINANCIAL OFFICER of this company sold 9,733 shares at a rate of $15.28, taking the stock ownership to the 43,735 shares. Before that another transaction happened on Aug 19 ’24, when Company’s EVP, COO, HEAD OF COMMERCIAL sold 9,534 for $15.28, making the entire transaction worth $145,680. This insider now owns 52,177 shares in total.
Acadia Pharmaceuticals Inc (ACAD) Latest Financial update
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.4 earnings per share (EPS), higher than consensus estimate (set at -0.43) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 246.15% per share during the next fiscal year.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Trading Performance Indicators
Take a look at Acadia Pharmaceuticals Inc’s (ACAD) current performance indicators. Last quarter, stock had a quick ratio of 1.95. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.76. Likewise, its price to free cash flow for the trailing twelve months is 30.59.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.18, a number that is poised to hit 0.14 in the next quarter and is forecasted to reach 0.82 in one year’s time.
Technical Analysis of Acadia Pharmaceuticals Inc (ACAD)
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) saw its 5-day average volume 1.38 million, a negative change from its year-to-date volume of 1.68 million. As of the previous 9 days, the stock’s Stochastic %D was 54.29%. Additionally, its Average True Range was 0.42.
During the past 100 days, Acadia Pharmaceuticals Inc’s (ACAD) raw stochastic average was set at 8.88%, which indicates a significant decrease from 33.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 25.37% in the past 14 days, which was lower than the 46.54% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.41, while its 200-day Moving Average is $17.93. Nevertheless, the first resistance level for the watch stands at $14.89 in the near term. At $15.17, the stock is likely to face the second major resistance level. The third major resistance level sits at $15.31. If the price goes on to break the first support level at $14.47, it is likely to go to the next support level at $14.33. The third support level lies at $14.05 if the price breaches the second support level.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Key Stats
The company with the Market Capitalisation of 2.46 billion has total of 165,876K Shares Outstanding. Its annual sales at the moment are 726,440 K in contrast with the sum of -61,290 K annual income. Company’s last quarter sales were recorded 241,960 K and last quarter income was 33,390 K.
